Sunday, May 17, 2026, Washington, DC, 8:00 AM – 9:30 AM Eastern Time

Second Opinion: Optimal Management of Localized Renal Cell Carcinoma

Part 1 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the 2026 American Urological Association Annual Meeting (AUA2026)

Register for in-person Register for webcast

Location
Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Program Schedule — Eastern Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

Meeting Room
Ballroom A, Third Level

No registration fee is charged for this event. For the in-person symposium in Washington, DC, preregistration is required to ensure seating.  
 
Faculty
Eric A Singer, MD, MA, MS
The Dave Longaberger Endowed Chair in Urology
Professor of Urology and Bioethics
Chief, Division of Urologic Oncology
Director, Urologic Oncology Fellowship
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Ulka Vaishampayan, MD
Beverly Mitchell Research Professor of Oncology
Co-Leader of Translational Clinical Research Program
University of Michigan/Rogel Cancer Center
Ann Arbor, Michigan

Moderator
Thomas E Hutson, DO, PharmD, PhD
Medical Oncology — Clinical Research Drug Development
Texas Oncology
GU Executive and Bridge Committees
Sarah Cannon Research Institute (SCRI)
Abilene, Texas




This activity is supported by an educational grant from Merck.
Program Schedule — Eastern Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

MODULE 1: Current Indications for Adjuvant Immune Checkpoint Inhibitor Therapy in the Management of Renal Cell Carcinoma (RCC)

  • Appropriate risk stratification for patients with localized RCC
  • Outcomes achieved with historical standards of care for localized RCC; biological rationale for the assessment of immune checkpoint inhibitors as adjuvant therapy
  • Key efficacy findings from the Phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence after nephrectomy; current clinical role of this strategy
  • Published data from Phase III studies, such as IMmotion010, CheckMate 914 Parts A and B, RAMPART and PROSPER RCC, demonstrating a lack of benefit with other (neo)adjuvant immune checkpoint inhibitor-based strategies for patients with RCC; efficacy advantages, if any, observed in specific subsets in these studies

MODULE 2: Potential Role of Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitors as a Component of Adjuvant Treatment

  • Biological rationale for targeting HIF-2α in patients with RCC; mechanism of action of belzutifan
  • Outcomes achieved with belzutifan for patients with advanced RCC and for those with von Hippel-Lindau-associated disease; current clinical role of this agent
  • Proposed synergy between belzutifan and PD-1 blockade by pembrolizumab
  • Recently presented findings from the Phase III LITESPARK-022 trial assessing the addition of belzutifan to pembrolizumab in the adjuvant setting for patients with high-risk clear cell RCC; potential clinical role of this strategy

MODULE 3: Tolerability of Current and Emerging Adjuvant Approaches for RCC

  • Incidence and spectrum of immune-mediated and other adverse events observed with adjuvant pembrolizumab for patients with RCC; recommended monitoring and management
  • Relative and absolute complications of immune checkpoint inhibitor therapy; role, if any, in treatment for patients with autoimmune disease or a history of transplant
  • Spectrum, frequency, severity and management of toxicities associated with belzutifan
  • Tolerability profile of belzutifan and pembrolizumab in combination in the LITESPARK-022 study

Target Audience
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate available clinical research data with adjuvant anti-PD-1/PD-L1 antibody therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, and provide appropriate counsel regarding guideline-endorsed treatment recommendations.
  • Optimize the current and future use of adjuvant therapy for patients with RCC, considering the influence of various clinical and biological factors.
  • Understand the biological rationale for the investigation of anti-PD-1/PD-L1 antibody therapy in combination with hypoxia-inducible factor 2 alpha inhibitors as adjuvant therapy for RCC, and consider emerging trial findings with and the potential role of this novel approach in clinical practice.
  • Discern the side effects and toxicities associated with available and investigational therapies used as adjuvant therapy for patients with RCC, and identify strategies to manage and mitigate them.
  • Recall ongoing trials evaluating novel agents and strategies as adjuvant therapy for RCC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Hutson — Advisory Committees, Consulting Agreements, Contracted Research and Speakers Bureaus: Astellas, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Exelixis Inc, Merck, Pfizer Inc, Seagen Inc. Additional faculty to be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Merck.

Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Meeting Room
Ballroom A, Third Level

Directions
The Walter E Washington Convention Center is the main venue for the 2026 AUA Annual Meeting.

This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma.

No registration fee is charged for this event. For the in-person symposium in Washington, DC, preregistration is required to ensure seating.

NOTICE:
Registration for this event is independent of registration for the 2026 AUA Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

We will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.